- Home
- NVNO
as 10-28-2025 2:05am EST
enVVeno Medical Corp is a late clinical-stage medical device company focused on advancing bioprosthetic (tissue-based) solutions to improve the standard of care for treating venous disease. The company's product, VenoValve, is a surgical replacement venous valve that is currently being evaluated in a U.S. pivotal study. The company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the products are designed to act as one-way valves to help assist in propelling blood up the veins of the leg, and back to the heart and lungs. The company has determined that it currently operates in a single segment, Medical Device development, located in a single geographic location, the United States.
Upcoming Earnings Alert:
Get ready for potential market movements as enVVeno Medical Corporation NVNO prepares to release earnings report on 31 Oct 2025.
| Founded: | 1987 | Country: | United States |
| Employees: | N/A | City: | IRVINE |
| Market Cap: | 16.7M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 331.1K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.20 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.67 - $5.62 | Next Earning Date: | 10-31-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest enVVeno Medical Corporation News
NVNO Breaking Stock News: Dive into NVNO Ticker-Specific Updates for Smart Investing
Simply Wall St.
4 months ago
Companies Like enVVeno Medical (NASDAQ:NVNO) Are In A Position To Invest In Growth
ACCESS Newswire
5 months ago
Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting
ACCESS Newswire
5 months ago
enVVeno Medical Appoints Jennifer Bright as Chief Financial Officer
ACCESS Newswire
5 months ago
Three-Year VenoValve(R) First-in-Human Trial Data Published in the Annals of Vascular Surgery
ACCESS Newswire
6 months ago
enVVeno Medical Reports First Quarter 2025 Financial Results and Reiterates Progress Toward VenoValve FDA Decision Expected in 2H24
ACCESS Newswire
6 months ago
VenoValve to be Featured During Presentation at the 47th Annual Charing Cross Symposium
ACCESS Newswire
6 months ago
enVVeno Medical to Participate in a Live Virtual Investor Closing Bell Segment
ACCESS Newswire
7 months ago
The Impact of the VenoValve(R) on Patients with Primary and Secondary Chronic Venous Insufficiency (CVI) to be Presented at the Society for Clinical Vascular Surgery 52nd Annual Symposium
Compare NVNO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NVNO enVVeno Medical Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.